A systematic review of filler agents for aesthetic treatment of HIV facial lipoatrophy (FLA).

[1]  B. Clotet,et al.  Ten-Year Safety with Polyacrylamide Gel Used to Correct Facial Lipoatrophy in HIV-Infected Patients. , 2015, AIDS Research and Human Retroviruses.

[2]  R. Rauso.  5-year study of a polyacrylamide hydrogel-based filler for rehabilitation of HIV-related facial lipoatrophy. , 2015, Aesthetic surgery journal.

[3]  D. Ho,et al.  Biological properties of a new volumizing hyaluronic acid filler: a systematic review. , 2015, Journal of drugs in dermatology : JDD.

[4]  K. Petribú,et al.  Treatment of facial lipoatrophy with polymethylmethacrylate among patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS): impact on the quality of life , 2014, International journal of dermatology.

[5]  Audrey S. Wang,et al.  The "smile-and-fill" injection technique: a dynamic approach to midface volumization. , 2014, Journal of drugs in dermatology : JDD.

[6]  P. Nieuwkerk,et al.  Semipermanent filler treatment of HIV-positive patients with facial lipoatrophy: long-term follow-up evaluating MR imaging and quality of life. , 2014, Aesthetic surgery journal.

[7]  Bassem Refaat,et al.  Evaluating MR Imaging and Quality of Life Semipermanent Filler Treatment of HIV-Positive Patients With Facial Lipoatrophy: Long-Term Follow-up , 2014 .

[8]  S. Luebberding,et al.  Facial volume augmentation in 2014: overview of different filler options. , 2013, Journal of drugs in dermatology : JDD.

[9]  G. Tartaro,et al.  Safety and Efficacy of One‐Step Rehabilitation of Human Immunodeficiency Virus‐Related Facial Lipoatrophy Using an Injectable Calcium Hydroxylapatite Dermal Filler , 2013, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[10]  J. Carruthers,et al.  HIV-associated facial lipoatrophy treated with injectable silicone oil: a pilot study. , 2013, Journal of the American Academy of Dermatology.

[11]  L. Oyafuso,et al.  An index for staging facial lipoatrophy and evaluation of the efficacy of the treatment with polymethylmethacrylate in HIV/AIDS patients: a pilot study , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[12]  R. Porcher,et al.  Polylactic acid vs. polyacrylamide hydrogel for treatment of facial lipoatrophy: a randomized controlled trial [Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) 132 SMILE] , 2013, HIV medicine.

[13]  I. Costa,et al.  Treatment of HIV-associated facial lipoatrophy: impact on infection progression assessed by viral load and CD4 count* , 2013, Anais brasileiros de dermatologia.

[14]  M. Duracinsky,et al.  High prevalence and impact on the quality of life of facial lipoatrophy and other abnormalities in fat tissue distribution in HIV-infected patients treated with antiretroviral therapy. , 2013, AIDS research and human retroviruses.

[15]  E. Erel,et al.  Patient satisfaction following Bio-Alcamid injection for facial contour defects. , 2012, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[16]  M. Loutfy,et al.  Infectious complications of Bio-Alcamid filler used for HIV-related facial lipoatrophy. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  A. LaMarca,et al.  Injectable Poly‐l‐Lactic Acid for Human Immunodeficiency Virus–Associated Facial Lipoatrophy: Cumulative Year 2 Interim Analysis of an Open‐Label Study (FACES) , 2012, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[18]  M. Duracinsky,et al.  Polyacrylamide hydrogel injection in the management of human immunodeficiency virus-related facial lipoatrophy: results of the LIPOPHILL open-label study. , 2012, AIDS research and human retroviruses.

[19]  G. Tartaro,et al.  A facial marker in facial wasting rehabilitation. , 2012, Journal of drugs in dermatology : JDD.

[20]  G. Guaraldi,et al.  Long-Term Efficacy and Safety of Polyacrylamide Hydrogel Injection in the Treatment of Human Immunodeficiency Virus–Related Facial Lipoatrophy: A 5-Year Follow-Up , 2012, Plastic and reconstructive surgery.

[21]  G. Tartaro,et al.  Polyacrylamide Gel for Facial Wasting Rehabilitation: How Many Milliliters per Session? , 2012, Aesthetic Plastic Surgery.

[22]  G. Guaraldi,et al.  High-density Hyaluronic Acid for the Treatment of HIV-related Facial Lipoatrophy , 2012, Aesthetic Plastic Surgery.

[23]  G. Tartaro,et al.  Polyacrylamide Gel Injection for Treatment of Human Immunodeficiency Virus‐Associated Facial Lipoatrophy: 18 Months Follow‐Up , 2011, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[24]  C. Kovacs,et al.  Four-Year Follow-Up of Polyalkylimide Gel Use for the Treatment of HIV-Associated Lipoatrophy , 2011, HIV clinical trials.

[25]  C. Talhari,et al.  Lipoatrophy in patients with AIDS: treatment with polymethylmethacrylate in Amazonas, Brazil , 2011, International journal of dermatology.

[26]  A. Gragnani,et al.  The impact of facial lipoatrophy treatment with polymethyl methacrylate in AIDS patients as measured by four quality-of-life questionnaires , 2011, International journal of STD & AIDS.

[27]  G. Tartaro,et al.  Comparison Between Lipofilling and a Nonabsorbable Filler for Facial Wasting Rehabilitation in HIV-Positive Patients , 2011, The Journal of craniofacial surgery.

[28]  Murad Alam,et al.  Large-particle calcium hydroxylapatite injection for correction of facial wrinkles and depressions. , 2011, Journal of the American Academy of Dermatology.

[29]  L. Nelson,et al.  Early and late complications of polyalkylimide gel (Bio-Alcamid)®. , 2011, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[30]  Å. Andersen,et al.  Polyacrylamide Gel Treatment of Antiretroviral Therapy-induced Facial Lipoatrophy in HIV Patients , 2011, Aesthetic Plastic Surgery.

[31]  T. Ruzicka,et al.  Monophasic, cohesive-polydensified-matrix crosslinking-technology-based hyaluronic acid filler for the treatment of facial lipoatrophy in HIV-infected patients. , 2010, Journal of drugs in dermatology : JDD.

[32]  H. Bugge,et al.  Large particle hyaluronic acid for the treatment of facial lipoatrophy in HIV‐positive patients: 3‐year follow‐up study , 2010, HIV medicine.

[33]  P. Butler,et al.  Objective evidence for the use of polylactic acid implants in HIV-associated facial lipoatrophy using three-dimensional surface laser scanning and psychological assessment. , 2009, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[34]  P. Narciso,et al.  Immediate versus delayed surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy: a randomized open-label study. , 2009, AIDS research and human retroviruses.

[35]  M. Neumann,et al.  Complications after Treatment with Polyalkylimide , 2009, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[36]  C. Kovacs,et al.  Long-term efficacy and safety of polyalkylimide gel for the treatment of HIV-associated lipoatrophy , 2009, AIDS care.

[37]  C. Salaro,et al.  Polymethylmethacrylate Facial Implant: A Successful Personal Experience in Brazil for More Than 9 Years , 2009, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[38]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[39]  R. Haubrich,et al.  Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment , 2009, AIDS.

[40]  C. Dollfus,et al.  Correction of facial lipoatrophy using autologous fat transplants in HIV‐infected adolescents , 2009, HIV medicine.

[41]  B. Clotet,et al.  Four-year safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophy. , 2009, AIDS research and human retroviruses.

[42]  S. Emery,et al.  Poly‐l‐lactic acid for HIV‐1 facial lipoatrophy: 48‐week follow‐up , 2009, HIV medicine.

[43]  G. Humble,et al.  Retreatment with Injectable Poly‐l‐Lactic Acid for HIV‐Associated Facial Lipoatrophy: 24‐Month Extension of the Blue Pacific Study , 2009, Dermatologic Surgery.

[44]  J. Hornberger,et al.  Cost consequences of HIV-associated lipoatrophy , 2008, AIDS care.

[45]  G. Humble,et al.  Duration of Correction for Human Immunodeficiency Virus-Associated Lipoatrophy After Retreatment with Injectable Poly-l-Lactic Acid , 2009, Aesthetic Plastic Surgery.

[46]  C. Hanke,et al.  Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: a prospective 3-year follow-up study. , 2008, Journal of the American Academy of Dermatology.

[47]  J. Carruthers,et al.  Evaluation of Injectable Calcium Hydroxylapatite for the Treatment of Facial Lipoatrophy Associated with Human Immunodeficiency Virus , 2008, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[48]  R. Rajagopalan,et al.  Impact of lipoatrophy on quality of life in HIV patients receiving anti-retroviral therapy1 , 2008, AIDS Care.

[49]  T. Gambichler,et al.  Hyaluronic Acid New Formulation: Experience in HIV-Associated Facial Lipoatrophy , 2008, Dermatology.

[50]  R. Fitzgerald,et al.  Poly-L-lactic acid injection for HIV-associated facial lipoatrophy: treatment principles, case studies, and literature review. , 2008, Aesthetic surgery journal.

[51]  J. Hönig.  Cheek Augmentation With Bio-Alcamid in Facial Lipoatrophy in HIV Seropositive Patients , 2008, The Journal of craniofacial surgery.

[52]  P. Nieuwkerk,et al.  Long-Term Effect of Polyalkylimide Gel Injections on Severity of Facial Lipoatrophy and Quality of Life of HIV-Positive Patients , 2008, Aesthetic Plastic Surgery.

[53]  J. Carruthers,et al.  Radiographic and Computed Tomographic Studies of Calcium Hydroxylapatite for Treatment of HIV–Associated Facial Lipoatrophy and Correction of Nasolabial Folds , 2008, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[54]  J. Catalan,et al.  The face of HIV and AIDS: can we erase the stigma? , 2008, AIDS care.

[55]  L. Nelson,et al.  Experience in the treatment of HIV-associated lipodystrophy. , 2008, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[56]  D. Thioly-Bensoussan.  Non-hyaluronic acid fillers. , 2008, Clinics in dermatology.

[57]  G. Guaraldi,et al.  Polyacrylamide Hydrogel Injection in the Management of Human Immunodeficiency Virus–Related Facial Lipoatrophy: A 2-Year Clinical Experience , 2008, Plastic and reconstructive surgery.

[58]  D. Cooper,et al.  A Randomized, Multicenter, Open-Label Study of Poly-L-Lactic Acid for HIV-1 Facial Lipoatrophy , 2007, Journal of acquired immune deficiency syndromes.

[59]  G. Guaraldi,et al.  Long-term psychometric outcomes of facial lipoatrophy therapy: forty-eight-week observational, nonrandomized study. , 2007, AIDS patient care and STDs.

[60]  M. Johnson,et al.  Does severity predict distress? The relationship between subjective and objective measures of appearance and psychological adjustment, during treatment for facial lipoatrophy. , 2007, Body image.

[61]  C. Kovacs,et al.  Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients , 2007, AIDS.

[62]  A. Denton,et al.  Injectable hyaluronic acid for the correction of HIV-associated facial lipoatrophy , 2007, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[63]  Y. Ullmann,et al.  Preliminary Experiences with Bio-Alcamid in HIV Facial Lipoatrophy , 2007, Dermatology.

[64]  C. Hanke,et al.  Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging. , 2007, Journal of drugs in dermatology : JDD.

[65]  B. Clotet,et al.  Reconstructive treatment for antiretroviral-associated facial lipoatrophy: a prospective study comparing autologous fat and synthetic substances. , 2006, AIDS patient care and STDs.

[66]  Derek H. Jones,et al.  Persistent Granulomatous Inflammatory Response Induced by Injectable Poly‐L‐lactic Acid for HIV Lipoatrophy , 2006, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[67]  G. Humble,et al.  Safety and Efficacy of Poly‐L‐lactic Acid Injections in Persons with HIV‐Associated Lipoatrophy: The US Experience , 2006, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[68]  F. Vichi,et al.  Treatment of human immunodeficiency virus-associated facial lipoatrophy with lipofilling and submalar silicone implants. , 2006, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[69]  J. Eviatar,et al.  Prospective, Open-Label, 18-Month Trial of Calcium Hydroxylapatite (Radiesse) for Facial Soft-Tissue Augmentation in Patients with Human Immunodeficiency Virus-Associated Lipoatrophy: One-Year Durability , 2006, Plastic and reconstructive surgery.

[70]  D. Goldberg,et al.  Use of a Biopolymer Polyalkylimide Filler for Facial Lipodystrophy in HIV‐Positive Patients Undergoing Treatment with Antiretroviral Drugs , 2006, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[71]  L. Lysakova,et al.  Long‐term safety and efficacy of poly‐L‐lactic acid in the treatment of HIV‐related facial lipoatrophy , 2006, HIV medicine.

[72]  S. Campostrini,et al.  Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy. , 2006, Archives of dermatology.

[73]  H. Korting,et al.  Deep Subcutaneous Application of Poly-L-Lactic Acid as a Filler for Facial Lipoatrophy in HIV-Infected Patients , 2005, Skin Pharmacology and Physiology.

[74]  N. Dupin,et al.  Evaluation of Coleman lipostructure for treatment of facial lipoatrophy in patients with human immunodeficiency virus and parameters associated with the efficiency of this technique. , 2005, Archives of dermatology.

[75]  G. Guaraldi,et al.  Comparison of Three Different Interventions for the Correction of HIV-Associated Facial Lipoatrophy: A Prospective Study , 2005, Antiviral therapy.

[76]  R. Porcher,et al.  Treatment of Facial Lipoatrophy With Intradermal Injections of Polylactic Acid in HIV-Infected Patients , 2005, Journal of acquired immune deficiency syndromes.

[77]  R. Quiroga,et al.  Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. , 2005, Journal of the American Academy of Dermatology.

[78]  M. Gooderham,et al.  Use of Hyaluronic Acid for Soft Tissue Augmentation of HIV‐Associated Facial Lipodystrophy , 2005, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[79]  S. Comite,et al.  Treatment of HIV-associated facial lipoatrophy with Radiance FN (Radiesse). , 2004, Dermatology online journal.

[80]  S. Azen,et al.  Highly Purified 1000‐cSt Silicone Oil for Treatment of Human Immunodeficiency Virus‐Associated Facial Lipoatrophy: An Open Pilot Trial , 2004, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[81]  Danny Vleggaar,et al.  Facial enhancement and the European experience with Sculptra (poly-l-lactic acid). , 2004, Journal of drugs in dermatology : JDD.

[82]  L. Lysakova,et al.  A randomized open‐label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection , 2004, HIV medicine.

[83]  B. Strauch,et al.  Treatment of Human Immunodeficiency Virus–Associated Lipodystrophy with Dermafat Graft Transfer to the Malar Area , 2004, Plastic and reconstructive surgery.

[84]  Philippe Katz,et al.  Polylactic acid implants (New-Fill)® to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA , 2003, AIDS.

[85]  A. Wu,et al.  Relationship Between HAART Adherence and Adipose Tissue Alterations , 2002, Journal of acquired immune deficiency syndromes.

[86]  J. Carruthers,et al.  HIV‐Associated Facial Lipoatrophy , 2002, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[87]  J. Moatti,et al.  Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy , 2001, AIDS.

[88]  T. Jh,et al.  Local treatment of facial lipodystrophy in patients receiving HIV protease inhibitor therapy. , 2001 .

[89]  D. Cooper,et al.  A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome , 2000, AIDS.

[90]  S. Coleman.  Facial recontouring with lipostructure. , 1997, Clinics in plastic surgery.